ART3, frequently overexpressed in triple negative breast cancer, is a novel diagnostic marker candidate for aggressive, poor prognosis breast cancer

1. Triple negative breast cancer (BC) is an aggressive, poor-prognosis of breast cancer for which a clear clinical need exists because this sub-type of BC is refractory to hormone-therapy and herceptin. Meta-analysis of 3 independent breast cancer data sets demonstrates that triple negative breast cancer, which does not express the traditional markers of BC including ESR, PGR, and Her2/Neu, contains significantly elevated levels of ART3 mRNA. Hence, ART3 is a novel candidate marker for triple negative BC. No previously published data about ART3 in triple negative breast cancer exist. I carried out the current BC meta-analysis on data produced by unrelated whole-genome expression technologies. I did so in order to reduce the chance of technology-specific errors. Please use the GEO IDs in the above table to find the specific data sources at GEO website. -MehisPold, M.D. E-mail: mehisp@hotmail.com Copyright © Eomix, Inc.